erlotinib hydrochloride has been researched along with Cancer of Esophagus in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 16 (59.26) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Baxter, MA; Petty, RD; Spender, LC | 1 |
| Bian, X; Chen, M; Ding, L; Du, D; Hu, W; Jiang, W; Jing, Z; Li, D; Lian, X; Liu, Q; Luo, H; Ma, L; Tan, B; Wang, L; Wu, S; Xia, B; Xie, C; Xie, R; Zhang, H; Zheng, A | 1 |
| Batchelder, E; Drabick, JJ; Lehrer, EJ; Machtay, M; Sharma, N; Tchelebi, LT; Trifiletti, DM; Wang, M; Zaorsky, NG | 1 |
| Amanuma, Y; Chiba, T; Ida, T; Kikuchi, O; Matsubara, J; Miyamoto, S; Muto, M; Nakagawa, H; Nakai, Y; Natsuizaka, M; Ohashi, S; Seno, H; Yamada, A; Yoshioka, M | 1 |
| Du, D; Fang, M; Song, T; Wu, S; Zhang, X | 1 |
| Lordick, F | 1 |
| Chhatrala, R; Iyer, R; Khushalani, N; Levea, C; Malhotra, U; Robins, M; Shefter, T; Tan, W; Yang, G | 1 |
| Bogatyreva, L; Braun, JA; Faller, G; Fichter, CD; Geddert, H; Gudernatsch, V; Hauschke, D; Klimstra, D; Lassmann, S; Schöpflin, A; Tang, L; Timme, S; Werner, M | 1 |
| Hatanaka, Y; Kagawa, S; Kinugasa, H; Komatsu, Y; Kubota, Y; Maehara, O; Marukawa, K; Nakagawa, H; Natsuizaka, M; Ohashi, S; Ohnishi, S; Sakamoto, N; Sato, F; Shimizu, Y; Suda, G; Terashita, K; Whelan, KA | 1 |
| Bass, AJ; Chen, T; Diehl, JA; Liu, JB; Nagaraja, A; Pectasides, E; Rustgi, AK; Sanchez-Vega, F; Sicinska, E; Stachler, M; Wong, G; Wong, KK; Wu, Z; Xu, X; Zhang, H; Zhou, J | 1 |
| Chen, Y; Ge, F; Jia, R; Jin, Y; Lin, L; Liu, J; Liu, R; Wang, Y; Xu, J; Zhao, C | 1 |
| Ahsan, A; Beer, DG; Hasan, MR; Kausar, T; Lin, L; Ralhan, R | 1 |
| Deng, X; Hu, W; Li, G; Wang, J; Wu, S; Xie, C; Zhang, P; Zhang, X | 1 |
| Boyd, J; Capanu, M; Ilson, DH; Kelsen, D; Klimstra, D; Levine, DA; Miron, B; Schwartz, G; Shah, M | 1 |
| Dao, KM; DiCarlo, B; Elashoff, R; Hecht, JR; Lin, LS; Park, DJ; Patel, R; Ryba, N; Wainberg, ZA; Wang, HJ | 1 |
| Chen, B; Hui, Z; Liang, J; Lv, J; Wang, J; Wang, L; Wang, X; Zhai, Y; Zhu, H; Zou, S | 1 |
| Bendell, JC; Burris, HA; Hainsworth, JD; Meluch, A; Peyton, J; Rubin, M; Waterhouse, D; Webb, C | 1 |
| Li, WF; Wu, SX; Xie, CY; Zhang, P; Zhang, XB | 1 |
| Fujii, H; Jimmy So, A; Kono, K; Mimura, K; Shabbir, A; Yong, WP | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Höpfner, M; Huether, A; Maaser, K; Scherübl, H; Sutter, AP | 1 |
| Bonner, JA; Clemons, LK; Dobelbower, MC; Posey, J; Raisch, KP; Russo, SM; Seay, LL; Suter, S | 1 |
| Abbruzzese, JL; Baker, AF; Benedetti, JK; Blanke, CD; Dragovich, T; Fenoglio-Preiser, CM; Hackett, CB; McCoy, S; Urba, SG; Wang, J; Zaner, KS | 1 |
| Personeni, N | 1 |
| Argiris, A; Grandis, JR; Karamouzis, MV | 1 |
| Black, JD; Iyer, RV; Javle, MM; Levea, CM; Maddipatla, S; Nwogu, CE; Pande, AU; Rani, A; Yang, GY | 1 |
5 review(s) available for erlotinib hydrochloride and Cancer of Esophagus
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies.
Topics: Bevacizumab; Brain Neoplasms; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Neoplasms; Outcome Assessment, Health Care; Panitumumab; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Delivery Systems; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab | 2012 |
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Epidermal growth factor receptor-directed therapy in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Humans; Incidence; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
12 trial(s) available for erlotinib hydrochloride and Cancer of Esophagus
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Male; Middle Aged; Paclitaxel | 2020 |
Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Prospective Studies; Quinazolines; Thoracic Duct | 2013 |
A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Paclitaxel; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Feasibility Studies; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Thrombocytopenia | 2010 |
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Mutation; Quinazolines; Retreatment | 2011 |
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Protein Kinase Inhibitors; Quinazolines | 2011 |
Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagitis; Exanthema; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Survival Rate | 2013 |
A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
[Phase II study of radiotherapy plus erlotinib for elder patients with esophageal carcinoma].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Neoplasm Staging; Quinazolines | 2012 |
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Topics: Biomarkers, Tumor; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
11 other study(ies) available for erlotinib hydrochloride and Cancer of Esophagus
| Article | Year |
|---|---|
Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Humans; Precision Medicine | 2020 |
Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Topics: Animals; Carcinoma, Squamous Cell; Cell Differentiation; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Male; Neoplasm Staging; Paclitaxel; Patient Compliance; Propensity Score; Radiotherapy, Conformal; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
More is more? Pushing chemoradiotherapy of oesophageal squamous cell carcinoma forward.
Topics: Chemoradiotherapy; Epithelial Cells; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans | 2018 |
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured | 2014 |
EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Homeodomain Proteins; Humans; Neoplastic Stem Cells; Spheroids, Cellular; Transcription Factors; Tumor Burden; Tumor Cells, Cultured; Zinc Finger E-box-Binding Homeobox 1 | 2015 |
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Amplification; Humans; Mice; Mitogen-Activated Protein Kinases; Phenotype; Protein Kinase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines.
Topics: Antigens, Surface; Antineoplastic Agents; Benzoquinones; Biomarkers, Tumor; Blotting, Western; Calmodulin-Binding Proteins; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Cisplatin; Erlotinib Hydrochloride; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunoprecipitation; Lactams, Macrocyclic; Mass Spectrometry; Membrane Proteins; Protein Binding; Protein Interaction Mapping; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2006 |
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?
Topics: ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2007 |